Bryan C F, Nelson P W, Shield C F, Warady B A, Winklhofer F T, Murillo D, Wakefield M R
Midwest Transplant Network, Westwood, KS, USA.
Am J Transplant. 2007 May;7(5):1181-4. doi: 10.1111/j.1600-6143.2007.01750.x. Epub 2007 Mar 12.
The long-term outcome of kidneys transplanted from blood group A(2) live donors into blood group O or B candidates is not known. From 1986 through 2006, we transplanted eight blood group O patients and one blood group B patient with kidneys from blood group A(2) live donors. Immunosuppression was no different for these patients than for ABO-compatible recipients. All patients received methylprednisolone, cyclosporine or tacrolimus and azathioprine or mycophenolate mofetil with or without antibody induction (monoclonal or polyclonal). Of the nine live-donor A(2) to O and B transplants performed, seven grafts remain functioning. One of those seven was lost to follow-up at 9.2 years with a functioning kidney. Of the remaining six patients, length of follow-up is 10.4, 6.5, 5.3, 4, 2.1 and 1 years. Of the two patients who lost their grafts, one died with a functioning graft (DWFG) at 8.8 years and one lost his graft at 13.2 years due to noncompliance with immunosuppression. These data show that good long-term graft survival can be expected in live-donor A(2) to O and B transplantation despite some of those patients experiencing the type of clinical problems seen with ABO-compatible transplants.
将 A(2) 血型活体供者的肾脏移植给 O 血型或 B 血型受者的长期结果尚不清楚。从 1986 年到 2006 年,我们为 8 名 O 血型患者和 1 名 B 血型患者移植了 A(2) 血型活体供者的肾脏。这些患者的免疫抑制与 ABO 血型相容的受者并无不同。所有患者均接受了甲泼尼龙、环孢素或他克莫司以及硫唑嘌呤或霉酚酸酯治疗,有或没有抗体诱导(单克隆或多克隆)。在进行的 9 例 A(2) 血型活体供者到 O 血型和 B 血型的移植中,7 个移植物仍在发挥功能。其中 1 个在随访 9.2 年时失访,当时肾脏功能正常。其余 6 例患者的随访时间分别为 10.4 年、6.5 年、5.3 年、4 年、2.1 年和 1 年。在 2 例移植物失功的患者中,1 例在 8.8 年时带功能移植物死亡(DWFG),1 例在 13.2 年时因未遵守免疫抑制治疗而移植物失功。这些数据表明,尽管部分患者出现了 ABO 血型相容移植中所见的临床问题类型,但 A(2) 血型活体供者到 O 血型和 B 血型的移植仍可预期获得良好的长期移植物存活。